Core Insights - LeonaBio has acquired a license for the Phase 3 development of lasofoxifene, a selective estrogen receptor modulator (SERM), which presents a potential multi-billion dollar opportunity for treating breast cancer patients with ESR1 mutations [1][5][3] - The company raised $90 million through private placement financing, with the potential for an additional $146 million from cash-exercisable warrants to support the development of lasofoxifene [1][3] - The Phase 3 clinical trial for lasofoxifene is expected to complete enrollment by Q4 2026, with topline data anticipated in the second half of 2027 [2][5] Clinical Development & Pipeline Programs - Lasofoxifene is designed to target both wild-type and mutant estrogen receptors, particularly for patients with ESR1 mutations who have limited treatment options [4][5] - The ongoing Phase 3 ELAINE-3 trial aims to establish a new standard of care for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, with an amendment to increase the sample size from 500 to 600 participants [5][4] - ATH-1105, another drug candidate, is being developed for ALS and is on track to initiate a Phase 2 proof-of-concept study in the second half of 2026 [2][6] Corporate Updates - The company transitioned from Athira Pharma to LeonaBio, reflecting a strategic evolution towards a more focused and diversified biopharmaceutical entity [3] - Mark F. Kubik was appointed as Chief Business Officer to oversee licensing and corporate development initiatives [6] - The name change aligns with the acquisition of lasofoxifene rights and emphasizes the company's commitment to innovation in treating unmet medical needs [6] Financial Results - As of December 31, 2025, LeonaBio reported cash and cash equivalents of $69.3 million, an increase from $48.4 million in 2024 [17] - Research and development expenses rose to $85.6 million in 2025, primarily due to costs associated with the lasofoxifene license [10][8] - The net loss for 2025 was $105.6 million, or $24.70 per share, compared to a net loss of $96.9 million, or $25.19 per share, in 2024 [14][21]

Core Viewpoint - Athira Pharma has acquired the rights to develop and commercialize lasofoxifene, a selective estrogen receptor modulator (SERM), for the treatment of metastatic breast cancer, representing a significant opportunity in a multi-billion dollar market [2][3][4]. Financing and Development - Athira announced a $90 million upfront financing through private placement, co-led by Commodore Capital, Perceptive Advisors, and TCGX, with potential additional funding of up to $146 million through warrants [4][9]. - The financing aims to support the development of lasofoxifene through key clinical and regulatory milestones, with sufficient capital projected to last into 2028 [4][9]. Clinical Trials and Data - The ongoing Phase 3 ELAINE-3 clinical trial is over 50% enrolled, with pivotal data expected in mid-2027 [2][19]. - Previous Phase 2 trials (ELAINE-1 and ELAINE-2) demonstrated lasofoxifene's potential, showing significant progression-free survival and objective response rates in heavily pre-treated patients [17][18]. Market Opportunity - The metastatic breast cancer treatment market is projected to grow from $17.1 billion in 2021 to $41.7 billion by 2030, with a compound annual growth rate (CAGR) of approximately 10.4% [14][15]. - Approximately 40% of breast cancer patients develop ESR1 mutations, creating a substantial market for lasofoxifene as a preferred endocrine therapy [5][14]. License Agreement Details - Athira has entered into a license agreement with Sermonix Pharmaceuticals, which includes a pre-funded warrant for approximately 5.5 million shares and potential milestone payments of up to $100 million based on commercialization success [6][9]. Company Overview - Athira Pharma is focused on developing novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and neurodegenerative diseases [23].

Core Viewpoint - Atossa Therapeutics is actively engaging with investors and the biotech community to discuss its clinical advancements and future milestones, particularly focusing on its lead product candidate, (Z)-endoxifen, which aims to innovate breast cancer treatment and prevention [1][3]. Group 1: Company Overview - Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment and prevention through innovative science and patient-focused solutions [6]. - The company's lead product candidate, (Z)-endoxifen, is being developed as a therapy across the breast cancer spectrum, including both prevention and treatment settings [6]. Group 2: Upcoming Events - Dr. Steven Quay, Chairman and CEO of Atossa, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 3:00 p.m. ET [1][3]. - The live presentation will be webcast, with a replay available for approximately 90 days on the company's investor website [4]. Group 3: Clinical Progress - Dr. Quay will provide updates on the clinical progress of (Z)-endoxifen, highlighting its dual mechanisms of action as a Selective Estrogen Receptor Modulator (SERM) that may offer a differentiated solution for breast cancer prevention and treatment [3]. - Recent feedback from regulatory advisors has been encouraging, which could potentially accelerate the company's development path [3].

Core Viewpoint - Atossa Therapeutics has received positive feedback from the FDA regarding its proposed dose optimization trial for (Z)-endoxifen, aimed at treating ER+/HER2- metastatic breast cancer, which is a significant milestone for the company [1][2][3] FDA Feedback and Clinical Development - The FDA's constructive responses affirm key elements of Atossa's clinical development plan, eliminating the need for a virtual pre-IND meeting and facilitating a potential IND submission by Q4 2025 [2][3] - The FDA supports Atossa's dose optimization strategy and agrees with the existing nonclinical data package, enhancing confidence in the company's regulatory approach [3][7] Dose Optimization Strategy - The FDA has confirmed that existing clinical and nonclinical data are sufficient to initiate Part A (monotherapy) of the proposed dose optimization study, providing guidance on study design enhancements [7] - Atossa plans to explore multiple dose levels in its upcoming clinical study to define the optimal dose for combination therapy, aligning with the FDA's Project Optimus initiative [6][7] Combination Study Support - The FDA agrees with the scientific rationale for combining (Z)-endoxifen with standard-of-care therapies for breast cancer, which helps narrow the strategic approach for the potential IND [7] Cardiac Safety and Nonclinical Data - The FDA has confirmed that Atossa's cardiac safety assessment plan, including ECGs and QT interval monitoring, is sufficient for the monotherapy portion of the trial [7] - The existing nonclinical safety data package is deemed adequate, allowing Atossa to proceed without additional toxicity studies [7] Next Steps and Strategic Momentum - Atossa will announce plans for the target patient population, combination backbone, and overall trial design for the upcoming dose-ranging study in the coming weeks [7] - The company is positioned to maintain strategic momentum and meet regulatory milestones, aiming to deliver (Z)-endoxifen to patients and enhance shareholder value [5][10] About (Z)-Endoxifen - (Z)-endoxifen is a potent Selective Estrogen Receptor Modulator (SERM) that inhibits and potentially degrades estrogen receptors, showing activity in tumors resistant to other therapies [8][10] - Atossa is developing an oral formulation of (Z)-endoxifen that is enteric-coated to ensure optimal bioavailability and therapeutic integrity [9] Clinical Trials and Intellectual Property - Atossa is prioritizing (Z)-endoxifen for metastatic breast cancer, currently evaluating it in three Phase 2 trials [10] - The program is supported by a growing global intellectual property portfolio, including recently issued U.S. patents [10]

Core Viewpoint - Atossa Therapeutics has been granted a new patent for (Z)-endoxifen formulations, enhancing its intellectual property portfolio and supporting its mission to advance breast cancer treatment [1][2][3] Group 1: Patent and Intellectual Property - The newly granted patent (U.S. Patent No. 12,281,056) includes 58 claims related to (Z)-endoxifen formulations, focusing on purity, stability, and therapeutic methods [2] - Atossa's patent estate now encompasses over 200 claims related to (Z)-endoxifen formulations and their clinical applications, reinforcing the company's leadership in targeted therapies for hormone receptor-positive breast cancer [3] Group 2: Product Development and Efficacy - (Z)-endoxifen is a potent Selective Estrogen Receptor Modulator (SERM) that may cause estrogen receptor degradation and has shown efficacy in patients resistant to other hormonal treatments [4] - The company is developing an oral formulation of (Z)-endoxifen designed to bypass the stomach, which converts a significant portion of the drug to an inactive form [5] - Clinical studies indicate that (Z)-endoxifen is well tolerated in women with and without breast cancer, and it is being studied for both treatment and prevention of breast cancer, including a program for metastatic breast cancer [5] Group 3: Company Mission and Vision - Atossa is dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions, aiming to improve the lives of millions of women while generating substantial value for shareholders [3][6]

Core Viewpoint - Atossa Therapeutics has been granted a new patent for enteric oral formulations of (Z)-endoxifen, enhancing its intellectual property portfolio and supporting its mission to develop innovative treatments for breast cancer [1][2][3]. Intellectual Property - The newly granted U.S. Patent No. 12,275,684 covers enteric oral formulations of (Z)-endoxifen and methods for treating hormone-dependent breast and reproductive tract disorders [2]. - Atossa's patent estate now includes multiple U.S. patents with over 100 claims related to (Z)-endoxifen formulations and their clinical applications, reinforcing the company's leadership in targeted therapies for hormone receptor-positive breast cancer [3]. Product Development - (Z)-endoxifen is a potent Selective Estrogen Receptor Modulator (SERM) that may cause estrogen receptor degradation and has shown efficacy in patients resistant to other hormonal treatments [4]. - Atossa is developing a proprietary oral formulation of (Z)-endoxifen designed to bypass the stomach, as acidic conditions convert a significant portion of (Z)-endoxifen to the inactive (E)-endoxifen [5]. - Clinical studies indicate that (Z)-endoxifen is well tolerated in women with and without breast cancer, and it is currently being studied for both treatment and prevention of breast cancer, including a program in metastatic breast cancer [5]. Company Overview - Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on transforming breast cancer treatment through innovative science and patient-centered solutions [6]. - The company's lead product candidate, (Z)-endoxifen, is designed for use across the breast cancer spectrum, including prevention, neoadjuvant, adjuvant, and metastatic settings [6].